Victoza (liraglutide) was approved June 17, 2019, for pediatric patients 10 years of age and older for the treatment of type 2 糖尿病. This is the first non-insulin drug approved to treat type 2 diabetes in children since metformin was approved for pediatric patients in 2000.
干细胞介导的衰老组织再生: 细胞和分子视角
干细胞介导的衰老组织再生: 细胞和分子视角 摘要 几乎所有组织的衰老都伴随着逐渐的功能衰退. 现代再生生物学研究基于干细胞的策略是否可以恢复结构完整性和生理性能 阅读更多
